Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment

Maojun Zhou; Hao Zheng; Yubin Li; Huichao Huang; Xiaoli Min; Shuyan Dai; Wenqiang Zhou; Zhuchu Chen; Guangyu Xu; Yongheng Chen

doi:doi:10.18632/aging.202554

← Back

Research Paper Volume 13, Issue 5 pp 6982—6998

Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment

Figure 2. Synthesis of compound Zeta55. (A) MeOH, SOCl₂, reflux, 3h, 95.5%; (B) cyclobutanone, KCN, HOAc, 80° C, 12h, 92.5%; (C) 4-cyano-3-trifluomethylbenzamine, thiophosgene, DMF, 70° C, 24h, 30.2%; (D) 1mol/L NaOH, MeOH, 20° C, 4h, 98.2%; (E) CDI, NH₂OH^.HCl, dry THF, 10h, 28.1%.